Metabolic and lifestyle risk factors for chemotherapy-induced peripheral neuropathy in taxane and platinum-treated patients: a systematic review

被引:23
|
作者
Timmins, Hannah C. [1 ]
Mizrahi, David [2 ]
Li, Tiffany [1 ]
Kiernan, Matthew C. [1 ,3 ,4 ]
Goldstein, David [2 ,5 ]
Park, Susanna B. [1 ]
机构
[1] Univ Sydney, Fac Med & Hlth, Brain & Mind Ctr, Sydney, NSW, Australia
[2] UNSW Sydney, Fac Med, Prince Wales Clin Sch, Sydney, NSW, Australia
[3] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia
[4] Royal Prince Alfred Hosp, Camperdown, NSW, Australia
[5] Prince Wales Hosp, Dept Med Oncol, Randwick, NSW, Australia
基金
英国医学研究理事会; 澳大利亚国家健康与医学研究理事会;
关键词
Chemotherapy; Neuropathy; Risk factors; Obesity; Diabetes; Physical activity; QUALITY-OF-LIFE; CANCER-PATIENTS; COLORECTAL-CANCER; PHYSICAL-ACTIVITY; BREAST-CANCER; SENSORY NEUROPATHY; BODY-MASS; EXERCISE; SURVIVORS; WOMEN;
D O I
10.1007/s11764-021-00988-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Chemotherapy-induced peripheral neurotoxicity (CIPN) is a common dose-limiting toxicity of cancer treatment causing functional impairment and impacting quality of life. Effective prevention and treatment of CIPN are lacking, and CIPN risk factors remain ill-defined. Metabolic syndrome and associated conditions have emerged as potential risk factors, due to their high prevalence and independent association with nerve dysfunction. This systematic review aimed to investigate the association between these common metabolic-lifestyle factors and CIPN. Methods Searches were undertaken using Medline, Embase, CINAHL, Scopus, and Web of Science databases, with additional studies identified from bibliographic references cited by original and review articles. Articles that analyzed metabolic-lifestyle risk factors associated with CIPN for patients treated with platinum- or taxane-based chemotherapy were included. Results Searches identified 6897 titles; 44 articles had full text review, with 26 studies included. Overall incidence of neuropathy ranged from 16.9 to 89.4%. Obesity had the most consistent patient-oriented evidence as a risk factor for CIPN, with moderate evidence suggesting diabetes did not increase CIPN incidence or severity. A limited number of studies supported an association with low physical activity and greater CIPN risk. Conclusions Comorbidities and lifestyle factors, particularly obesity and low physical activity, may contribute to the development of CIPN. The implementation of sensitive outcome measures in large-scale clinical trials is required to further elucidate CIPN risk factors and evaluate if changes in lifestyle would improve long-term CIPN outcomes for cancer survivors. Implications for Cancer Survivors Better understanding of CIPN risk profiles may inform personalized medicine strategies and help elucidate pathophysiological mechanisms which could be targeted for neuroprotection.
引用
收藏
页码:222 / 236
页数:15
相关论文
共 50 条
  • [31] Effects of Exercise on Balance in Cancer Survivors With Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review and Meta-analysis
    Khemthong, Usa
    Hawsawi, Samah
    Schneider, Joanne Kraenzle
    CANCER NURSING, 2024,
  • [32] Concomitant Medications and Risk of Chemotherapy-Induced Peripheral Neuropathy
    Sanchez-Barroso, Lara
    Apellaniz-Ruiz, Maria
    Gutierrez-Gutierrez, Gerardo
    Santos, Maria
    Roldan-Romero, Juan M.
    Curras, Maria
    Remacha, Laura
    Calsina, Bruna
    Calvo, Isabel
    Sereno, Maria
    Merino, Maria
    Garcia-Donas, Jess
    Castelo, Beatriz
    Guerra, Eva
    Leton, Rocio
    Montero-Conde, Cristina
    Cascon, Alberto
    Inglada-Perez, Luca
    Robledo, Mercedes
    Rodriguez-Antona, Cristina
    ONCOLOGIST, 2019, 24 (08): : E784 - E792
  • [33] Chemotherapy-induced peripheral neuropathy: a review of recent findings
    Kim, Peggy Y.
    Johnson, Carrie E.
    CURRENT OPINION IN ANESTHESIOLOGY, 2017, 30 (05) : 570 - 576
  • [34] Falls and Functional Impairments in Breast Cancer Patients with Chemotherapy-Induced Peripheral Neuropathy
    Komatsu, Hiroko
    Yagasaki, Kaori
    Komatsu, Yasuhiro
    Yamauchi, Hideko
    Yamauchi, Teruo
    Shimokawa, Toshio
    Doorenbos, Ardith Z.
    ASIA-PACIFIC JOURNAL OF ONCOLOGY NURSING, 2019, 6 (03) : 253 - 260
  • [35] Quality of life of ovarian cancer patients treated with combined platinum taxane chemotherapy: a systematic review of the literature
    Pergialiotis, Vasilios
    Sotiropoulou, Ioanna Myrto
    Liatsou, Efstathia
    Liontos, Michalis
    Frountzas, Maximos
    Thomakos, Nikolaos
    Rodolakis, Alexandros
    Haidopoulos, Dimitrios
    SUPPORTIVE CARE IN CANCER, 2022, 30 (09) : 7147 - 7157
  • [36] Current use of drugs affecting the central nervous system for chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review
    Chu, Sang Hui
    Lee, Young Joo
    Lee, Eon Sook
    Geng, Yimin
    Wang, Xin Shelley
    Cleeland, Charles S.
    SUPPORTIVE CARE IN CANCER, 2015, 23 (02) : 513 - 524
  • [37] BMI, Lifestyle Factors and Taxane-Induced Neuropathy in Breast Cancer Patients: The Pathways Study
    Greenlee, Heather
    Hershman, Dawn L.
    Shi, Zaixing
    Kwan, Marilyn L.
    Ergas, Isaac J.
    Roh, Janise M.
    Kushi, Lawrence H.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2017, 109 (02):
  • [38] Diabetes mellitus as a risk factor for chemotherapy-induced peripheral neuropathy: a meta-analysis
    Gu, Jialin
    Lu, Hong
    Chen, Chen
    Gu, Zhancheng
    Hu, Miao
    Liu, Ling
    Yu, Jialin
    Wei, Guoli
    Huo, Jiege
    SUPPORTIVE CARE IN CANCER, 2021, 29 (12) : 7461 - 7469
  • [39] Psychosocial adaptation and influencing factors among patients with chemotherapy-induced peripheral neuropathy
    Zhou, Xiao
    Wang, Dong-Yang
    Ding, Cai-Yan
    Liu, Hui
    Sun, Zhi-Qin
    WORLD JOURNAL OF CLINICAL CASES, 2022, 10 (15) : 4843 - 4855
  • [40] Open REVIEW The Efficacy of Neuromodulation Interventions for Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review and Meta
    Xu, Runbing
    Yu, Changhe
    Zhang, Xinyu
    Zhang, Yipin
    Li, Mengfei
    Jia, Bei
    Yan, Shiyan
    Jiang, Miao
    JOURNAL OF PAIN RESEARCH, 2024, 17 : 1423 - 1439